459 related articles for article (PubMed ID: 17919258)
1. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
Pacher P; Szabó C
Cardiovasc Drug Rev; 2007; 25(3):235-60. PubMed ID: 17919258
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
3. Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease.
Pacher P; Szabo C
Am J Pathol; 2008 Jul; 173(1):2-13. PubMed ID: 18535182
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions.
Szabó C
Curr Vasc Pharmacol; 2005 Jul; 3(3):301-3. PubMed ID: 16026326
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
Virág L; Szabó C
Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
[TBL] [Abstract][Full Text] [Related]
6. Poly (ADP-ribose) polymerase activation and circulatory shock.
Szabó C
Novartis Found Symp; 2007; 280():92-103; discussion 103-7, 160-4. PubMed ID: 17380790
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose) polymerase inhibitors.
Southan GJ; Szabó C
Curr Med Chem; 2003 Feb; 10(4):321-40. PubMed ID: 12570705
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.
Curtin NJ; Szabo C
Mol Aspects Med; 2013 Dec; 34(6):1217-56. PubMed ID: 23370117
[TBL] [Abstract][Full Text] [Related]
9. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations.
Geraets L; Moonen HJ; Wouters EF; Bast A; Hageman GJ
Biochem Pharmacol; 2006 Sep; 72(7):902-10. PubMed ID: 16870158
[TBL] [Abstract][Full Text] [Related]
10. Minocycline protects cardiac myocytes against simulated ischemia–reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1.
Tao R; Kim SH; Honbo N; Karliner JS; Alano CC
J Cardiovasc Pharmacol; 2010 Dec; 56(6):659-68. PubMed ID: 20881608
[TBL] [Abstract][Full Text] [Related]
11. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
[TBL] [Abstract][Full Text] [Related]
12. Role of nitrosative stress and activation of poly(ADP-ribose) polymerase-1 in cardiovascular failure associated with septic and hemorrhagic shock.
Evgenov OV; Liaudet L
Curr Vasc Pharmacol; 2005 Jul; 3(3):293-9. PubMed ID: 16026325
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Horvath EM; Szabó C
Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
[TBL] [Abstract][Full Text] [Related]
14. The pathogenesis of diabetic complications: the role of DNA injury and poly(ADP-ribose) polymerase activation in peroxynitrite-mediated cytotoxicity.
Kiss L; Szabó C
Mem Inst Oswaldo Cruz; 2005 Mar; 100 Suppl 1():29-37. PubMed ID: 15962096
[TBL] [Abstract][Full Text] [Related]
15. Novel modulators of poly(ADP-ribose) polymerase.
Szabo C; Pacher P; Swanson RA
Trends Pharmacol Sci; 2006 Dec; 27(12):626-30. PubMed ID: 17055069
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
de la Lastra CA; Villegas I; Sánchez-Fidalgo S
Curr Pharm Des; 2007; 13(9):933-62. PubMed ID: 17430191
[TBL] [Abstract][Full Text] [Related]
17. Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma.
Komjáti K; Besson VC; Szabó C
Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):179-94. PubMed ID: 15857303
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.
Pacher P; Liaudet L; Mabley JG; Cziráki A; Haskó G; Szabó C
Int J Mol Med; 2006 Feb; 17(2):369-75. PubMed ID: 16391839
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
20. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
Virág L
Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
